Semaglutide vs Empagliflozin: Which Drug Has Better Real-World Adherence?

Medication adherence comparison between semaglutide and empagliflozin in T2D found differences in persistence and compliance, informing drug selection for treatment sustainability.

Ali, Mostafa A S et al.·Patient preference and adherence·2025·Moderate Evidencecohort
RPEP-09865CohortModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
cohort
Evidence
Moderate Evidence
Sample
N=medium
Participants
Adults with type 2 diabetes at a military hospital in Tabuk, Saudi Arabia

What This Study Found

Medication adherence comparison between semaglutide and empagliflozin in T2D found differences in persistence and compliance, informing drug selection for treatment sustainability.

Key Numbers

Retrospective study comparing adherence and persistence between semaglutide and empagliflozin using pharmacy dispensing data.

How They Did This

Study methodology detailed in the full publication.

Why This Research Matters

These findings have practical implications for the growing number of patients using peptide-based therapies.

The Bigger Picture

This study contributes to the expanding evidence for peptide therapeutics in clinical practice.

What This Study Doesn't Tell Us

Study limitations in the full publication.

Questions This Raises

  • ?What are the long-term implications?
  • ?How do results compare to other evidence?
  • ?What further research is needed?

Trust & Context

Key Stat:
Key finding Medication adherence comparison between semaglutide and empagliflozin in T2D found differences in pe
Evidence Grade:
Evidence level based on study design in publication.
Study Age:
Published in 2025.
Original Title:
Medication Adherence to Semaglutide versus Empagliflozin in Adults with Type 2 Diabetes: A Retrospective Observational Study in Saudi Arabia.
Published In:
Patient preference and adherence, 19, 4179-4190 (2025)
Database ID:
RPEP-09865

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What does this mean for patients?

Medication adherence comparison between semaglutide and empagliflozin in T2D found differences in persistence and compliance, informing drug selection for treatment sustainability.

How reliable is this?

Consult the full publication and healthcare provider.

Read More on RethinkPeptides

Cite This Study

RPEP-09865·https://rethinkpeptides.com/research/RPEP-09865

APA

Ali, Mostafa A S; Amirthalingam, Palanisamy; Alshareef, Hanan; Alqifari, Saleh F; Elsaid Hamdan, Ahmed Mohsen; Alatawi, Olayan; Hakami, Faris Ahmed M; Albalawi, Nader Salem; Aljabri, Ahmed. (2025). Medication Adherence to Semaglutide versus Empagliflozin in Adults with Type 2 Diabetes: A Retrospective Observational Study in Saudi Arabia.. Patient preference and adherence, 19, 4179-4190. https://doi.org/10.2147/PPA.S569096

MLA

Ali, Mostafa A S, et al. "Medication Adherence to Semaglutide versus Empagliflozin in Adults with Type 2 Diabetes: A Retrospective Observational Study in Saudi Arabia.." Patient preference and adherence, 2025. https://doi.org/10.2147/PPA.S569096

RethinkPeptides

RethinkPeptides Research Database. "Medication Adherence to Semaglutide versus Empagliflozin in ..." RPEP-09865. Retrieved from https://rethinkpeptides.com/research/ali-2025-medication-adherence-to-semaglutide

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.